|
Gene: PABPN1 |
Gene summary for PABPN1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | PABPN1 | Gene ID | 8106 |
Gene name | poly(A) binding protein nuclear 1 | |
Gene Alias | OPMD | |
Cytomap | 14q11.2 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q86U42 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
8106 | PABPN1 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.81e-30 | 6.98e-01 | 0.0155 |
8106 | PABPN1 | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.20e-29 | 1.04e+00 | -0.1808 |
8106 | PABPN1 | HTA11_2951_2000001011 | Human | Colorectum | AD | 1.84e-06 | 7.26e-01 | 0.0216 |
8106 | PABPN1 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.40e-39 | 1.43e+00 | -0.0811 |
8106 | PABPN1 | HTA11_78_2000001011 | Human | Colorectum | AD | 1.93e-21 | 8.98e-01 | -0.1088 |
8106 | PABPN1 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.18e-71 | 1.41e+00 | -0.1954 |
8106 | PABPN1 | HTA11_411_2000001011 | Human | Colorectum | SER | 9.96e-12 | 1.24e+00 | -0.2602 |
8106 | PABPN1 | HTA11_2112_2000001011 | Human | Colorectum | SER | 3.60e-20 | 1.29e+00 | -0.2196 |
8106 | PABPN1 | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.37e-20 | 1.01e+00 | -0.1207 |
8106 | PABPN1 | HTA11_83_2000001011 | Human | Colorectum | SER | 7.01e-24 | 9.50e-01 | -0.1526 |
8106 | PABPN1 | HTA11_696_2000001011 | Human | Colorectum | AD | 2.86e-56 | 1.23e+00 | -0.1464 |
8106 | PABPN1 | HTA11_866_2000001011 | Human | Colorectum | AD | 9.57e-37 | 8.77e-01 | -0.1001 |
8106 | PABPN1 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.99e-48 | 1.45e+00 | -0.059 |
8106 | PABPN1 | HTA11_2992_2000001011 | Human | Colorectum | SER | 3.35e-18 | 8.80e-01 | -0.1706 |
8106 | PABPN1 | HTA11_5212_2000001011 | Human | Colorectum | AD | 2.53e-08 | 7.31e-01 | -0.2061 |
8106 | PABPN1 | HTA11_5216_2000001011 | Human | Colorectum | SER | 6.52e-10 | 8.86e-01 | -0.1462 |
8106 | PABPN1 | HTA11_546_2000001011 | Human | Colorectum | AD | 7.61e-18 | 1.01e+00 | -0.0842 |
8106 | PABPN1 | HTA11_9341_2000001011 | Human | Colorectum | SER | 2.42e-08 | 8.97e-01 | -0.00410000000000005 |
8106 | PABPN1 | HTA11_7862_2000001011 | Human | Colorectum | AD | 4.49e-25 | 1.17e+00 | -0.0179 |
8106 | PABPN1 | HTA11_866_3004761011 | Human | Colorectum | AD | 9.33e-48 | 1.21e+00 | 0.096 |
Page: 1 2 3 4 5 6 7 8 9 10 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0006913 | Colorectum | AD | nucleocytoplasmic transport | 102/3918 | 301/18723 | 1.00e-07 | 4.85e-06 | 102 |
GO:0051169 | Colorectum | AD | nuclear transport | 102/3918 | 301/18723 | 1.00e-07 | 4.85e-06 | 102 |
GO:0006403 | Colorectum | AD | RNA localization | 71/3918 | 201/18723 | 1.54e-06 | 4.76e-05 | 71 |
GO:0051236 | Colorectum | AD | establishment of RNA localization | 58/3918 | 166/18723 | 1.95e-05 | 4.01e-04 | 58 |
GO:0015931 | Colorectum | AD | nucleobase-containing compound transport | 73/3918 | 222/18723 | 2.02e-05 | 4.10e-04 | 73 |
GO:0050657 | Colorectum | AD | nucleic acid transport | 57/3918 | 163/18723 | 2.22e-05 | 4.39e-04 | 57 |
GO:0050658 | Colorectum | AD | RNA transport | 57/3918 | 163/18723 | 2.22e-05 | 4.39e-04 | 57 |
GO:0051168 | Colorectum | AD | nuclear export | 53/3918 | 154/18723 | 6.89e-05 | 1.11e-03 | 53 |
GO:0051028 | Colorectum | AD | mRNA transport | 42/3918 | 130/18723 | 1.57e-03 | 1.32e-02 | 42 |
GO:00069131 | Colorectum | SER | nucleocytoplasmic transport | 77/2897 | 301/18723 | 3.39e-06 | 1.32e-04 | 77 |
GO:00511691 | Colorectum | SER | nuclear transport | 77/2897 | 301/18723 | 3.39e-06 | 1.32e-04 | 77 |
GO:00064031 | Colorectum | SER | RNA localization | 53/2897 | 201/18723 | 4.51e-05 | 1.13e-03 | 53 |
GO:00511681 | Colorectum | SER | nuclear export | 42/2897 | 154/18723 | 1.19e-04 | 2.46e-03 | 42 |
GO:00159311 | Colorectum | SER | nucleobase-containing compound transport | 54/2897 | 222/18723 | 3.65e-04 | 5.67e-03 | 54 |
GO:00512361 | Colorectum | SER | establishment of RNA localization | 42/2897 | 166/18723 | 6.70e-04 | 8.96e-03 | 42 |
GO:00506571 | Colorectum | SER | nucleic acid transport | 41/2897 | 163/18723 | 8.74e-04 | 1.06e-02 | 41 |
GO:00506581 | Colorectum | SER | RNA transport | 41/2897 | 163/18723 | 8.74e-04 | 1.06e-02 | 41 |
GO:0003012 | Colorectum | SER | muscle system process | 92/2897 | 452/18723 | 2.98e-03 | 2.63e-02 | 92 |
GO:00069132 | Colorectum | MSS | nucleocytoplasmic transport | 99/3467 | 301/18723 | 1.35e-09 | 1.03e-07 | 99 |
GO:00511692 | Colorectum | MSS | nuclear transport | 99/3467 | 301/18723 | 1.35e-09 | 1.03e-07 | 99 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa03015 | Colorectum | AD | mRNA surveillance pathway | 35/2092 | 97/8465 | 7.95e-03 | 3.13e-02 | 2.00e-02 | 35 |
hsa030151 | Colorectum | AD | mRNA surveillance pathway | 35/2092 | 97/8465 | 7.95e-03 | 3.13e-02 | 2.00e-02 | 35 |
hsa030159 | Esophagus | HGIN | mRNA surveillance pathway | 30/1383 | 97/8465 | 2.48e-04 | 2.69e-03 | 2.14e-03 | 30 |
hsa0516420 | Esophagus | HGIN | Influenza A | 42/1383 | 171/8465 | 3.41e-03 | 2.54e-02 | 2.02e-02 | 42 |
hsa0301514 | Esophagus | HGIN | mRNA surveillance pathway | 30/1383 | 97/8465 | 2.48e-04 | 2.69e-03 | 2.14e-03 | 30 |
hsa05164110 | Esophagus | HGIN | Influenza A | 42/1383 | 171/8465 | 3.41e-03 | 2.54e-02 | 2.02e-02 | 42 |
hsa0516425 | Esophagus | ESCC | Influenza A | 122/4205 | 171/8465 | 5.01e-09 | 4.79e-08 | 2.45e-08 | 122 |
hsa0301524 | Esophagus | ESCC | mRNA surveillance pathway | 72/4205 | 97/8465 | 6.12e-07 | 4.10e-06 | 2.10e-06 | 72 |
hsa0516435 | Esophagus | ESCC | Influenza A | 122/4205 | 171/8465 | 5.01e-09 | 4.79e-08 | 2.45e-08 | 122 |
hsa0301534 | Esophagus | ESCC | mRNA surveillance pathway | 72/4205 | 97/8465 | 6.12e-07 | 4.10e-06 | 2.10e-06 | 72 |
hsa030154 | Liver | Cirrhotic | mRNA surveillance pathway | 46/2530 | 97/8465 | 1.92e-04 | 1.30e-03 | 8.03e-04 | 46 |
hsa0516410 | Liver | Cirrhotic | Influenza A | 66/2530 | 171/8465 | 8.56e-03 | 2.91e-02 | 1.79e-02 | 66 |
hsa0301511 | Liver | Cirrhotic | mRNA surveillance pathway | 46/2530 | 97/8465 | 1.92e-04 | 1.30e-03 | 8.03e-04 | 46 |
hsa0516411 | Liver | Cirrhotic | Influenza A | 66/2530 | 171/8465 | 8.56e-03 | 2.91e-02 | 1.79e-02 | 66 |
hsa0301521 | Liver | HCC | mRNA surveillance pathway | 66/4020 | 97/8465 | 3.16e-05 | 1.88e-04 | 1.04e-04 | 66 |
hsa0516421 | Liver | HCC | Influenza A | 101/4020 | 171/8465 | 1.41e-03 | 5.07e-03 | 2.82e-03 | 101 |
hsa0301531 | Liver | HCC | mRNA surveillance pathway | 66/4020 | 97/8465 | 3.16e-05 | 1.88e-04 | 1.04e-04 | 66 |
hsa0516431 | Liver | HCC | Influenza A | 101/4020 | 171/8465 | 1.41e-03 | 5.07e-03 | 2.82e-03 | 101 |
hsa030158 | Oral cavity | OSCC | mRNA surveillance pathway | 75/3704 | 97/8465 | 1.30e-11 | 2.01e-10 | 1.02e-10 | 75 |
hsa0516418 | Oral cavity | OSCC | Influenza A | 116/3704 | 171/8465 | 1.23e-10 | 1.78e-09 | 9.08e-10 | 116 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PABPN1 | insertion | In_Frame_Ins | novel | c.87_88insGGGGCCGGTGGG | p.Gly30_Gly33dup | p.G30_G33dup | Q86U42 | protein_coding | TCGA-DD-AAD8-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
PABPN1 | SNV | Missense_Mutation | c.872N>T | p.Arg291Leu | p.R291L | Q86U42 | protein_coding | deleterious(0.01) | probably_damaging(0.982) | TCGA-50-5049-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
PABPN1 | SNV | Missense_Mutation | c.904N>C | p.Trp302Arg | p.W302R | Q86U42 | protein_coding | deleterious(0.04) | possibly_damaging(0.648) | TCGA-86-7701-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | etoposide | PD | |
PABPN1 | SNV | Missense_Mutation | novel | c.632N>T | p.His211Leu | p.H211L | Q86U42 | protein_coding | deleterious(0) | possibly_damaging(0.472) | TCGA-L9-A444-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PABPN1 | SNV | Missense_Mutation | novel | c.857G>A | p.Ser286Asn | p.S286N | Q86U42 | protein_coding | tolerated(0.11) | benign(0) | TCGA-52-7811-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
PABPN1 | SNV | Missense_Mutation | novel | c.542N>G | p.Tyr181Cys | p.Y181C | Q86U42 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-CV-A45U-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
PABPN1 | SNV | Missense_Mutation | novel | c.676N>A | p.Val226Met | p.V226M | Q86U42 | protein_coding | tolerated(0.05) | probably_damaging(0.968) | TCGA-D6-6516-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
PABPN1 | SNV | Missense_Mutation | novel | c.677N>A | p.Val226Glu | p.V226E | Q86U42 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-D6-6516-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
PABPN1 | SNV | Missense_Mutation | novel | c.880N>G | p.Arg294Gly | p.R294G | Q86U42 | protein_coding | deleterious(0.01) | benign(0.275) | TCGA-UF-A7JS-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
PABPN1 | SNV | Missense_Mutation | c.802G>A | p.Ala268Thr | p.A268T | Q86U42 | protein_coding | tolerated(0.07) | benign(0.018) | TCGA-HU-A4G9-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |